IMMEDIATE AND LONG-TERM EFFECTS OF CLOFIBRATE ON THE METABOLISM OF THE PERFUSED RAT-LIVER

被引:42
作者
LAKER, ME
MAYES, PA
机构
[1] Department of Physiology and Biochemistry, Royal Veterinary College, London
基金
英国医学研究理事会;
关键词
D O I
10.1016/0006-2952(79)90567-7
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A study was made of the immediate effects of CPIB (chlorophenoxy-isobutyrate) and of the effects of clofibrate (ethyl-CPIB) pretreatment on the metabolism of the perfused liver. Both treatments caused an increased hepatic uptake of lactate and free fatty acids. Pretreatment with clofibrate resulted in a decrease in perfusate glucose, an increase in ketogenesis and a decreased output of very low density lipoprotein triacylglycerol. A more oxidized redox state of both the cytosol and the mitochondria was indicated by decreased ratios of perfusate [lactate]/[pyruvate] and [3-hydroxybutyrate]/[acetoacetate] respectively. Increased hepatic O2 consumption was associated with the increased liver weight of rats treated with the drug for 1 week. The fate of free fatty acids was followed by infusing [1-14Cloleate. The increased oxidation of oleate to both CO2 and ketone bodies in livers from animals pretreated with clofibrate was accompanied by a corresponding decreased incorporation of 14C into very low density lipoprotein triacylglycerol. Lipogenesis was depressed upon addition of CPIB to the perfusate, but was increased after pretreatment with clofibrate. No changes in cholesterol synthesis were detected. A hypothesis to account for the hypolipidaemic and other effects of clofibrate pretreatment is advanced. This is based on a primary enhancement of fatty acid oxidation accompanied by a reciprocal decrease in hepatic triacylglycerol secretion. It is suggested that increased peroxisomal oxidation of fatty acids may be a cause of the decreased redox potential. A consequent activation of pyruvate dehydrogenase would explain both the changes in carbohydrate metabolism and the increase in lipogenesis. © 1979.
引用
收藏
页码:2813 / 2827
页数:15
相关论文
共 73 条
[1]  
[Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P360
[2]  
AVOY DR, 1965, J LIPID RES, V6, P369
[3]   STUDIES WITH ETHYL CHLOROPHENOXYISOBUTYRATE (CLOFIBRATE) [J].
AZARNOFF, DL ;
TUCKER, DR ;
BARR, GA .
METABOLISM, 1965, 14 (09) :959-&
[5]   STIMULATION OF HEPATIC TRIGLYCERIDE SYNTHESIS AND SECRETION BY CLOFIBRATE [J].
CAPUZZI, DM ;
LACKMAN, RD ;
UBERTI, MO ;
REED, MA .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1974, 60 (04) :1499-1508
[6]  
CARLSON LARS A., 1959, ACTA SOC MED UPSALIENSIS, V64, P208
[7]   EFFECT OF CHRONIC CLOFIBRATE ADMINISTRATION ON MITOCHONDRIAL FATTY-ACID OXIDATION [J].
CEDERBAUM, AI ;
MADHAVAN, TV ;
RUBIN, E .
BIOCHEMICAL PHARMACOLOGY, 1976, 25 (11) :1285-1292
[8]   EFFECTS OF ETHYL-P-CHLOROPHENOXYISOBUTYRATE CLOFIBRATE ON PLASMA AND RED BLOOD CELL FREE FATTY ACIDS OF RAT [J].
CENEDELLA, RJ ;
JARRELL, JJ ;
SAXE, LH .
JOURNAL OF ATHEROSCLEROSIS RESEARCH, 1968, 8 (06) :903-+
[9]  
CHENG CY, 1970, CIRCULATION, V42, pIII2
[10]  
COHEN BI, BIOCH BIOPHYS ACTA, V369, P79